Display options
Cite
Nagi NMS, Khair YAM, Abdalla AME. Capacity of gold nanoparticles in cancer radiotherapy. Jpn J Radiol. 2017;35(10):555-561doi: 10.1007/s11604-017-0671-6.
Nagi, N. M. S., Khair, Y. A. M., & Abdalla, A. M. E. (2017). Capacity of gold nanoparticles in cancer radiotherapy. Japanese journal of radiology, 35(10), 555-561. https://doi.org/10.1007/s11604-017-0671-6
Nagi, Nadeem M S, et al. "Capacity of gold nanoparticles in cancer radiotherapy." Japanese journal of radiology vol. 35,10 (2017): 555-561. doi: https://doi.org/10.1007/s11604-017-0671-6
Nagi NMS, Khair YAM, Abdalla AME. Capacity of gold nanoparticles in cancer radiotherapy. Jpn J Radiol. 2017 Oct;35(10):555-561. doi: 10.1007/s11604-017-0671-6. Epub 2017 Aug 09. PMID: 28795273.
Copy Download .nbib Format: NLM
Share it on

Jpn J Radiol. 2017 Oct;35(10):555-561. doi: 10.1007/s11604-017-0671-6. Epub 2017 Aug 09.

Capacity of gold nanoparticles in cancer radiotherapy.

Japanese journal of radiology

Nadeem M S Nagi, Yasir A M Khair, Ahmed M E Abdalla

Affiliations

  1. Department of Oncology, King Khaled Hospital, King Abdulaziz Road, Najran, 61441, Saudi Arabia.
  2. Department of Biochemistry and Molecular Biology, College of Applied Science, University of Bahri, Bahri El-Ingaz Street, West Railway, P.O Box 1660, 11111, Khartoum, Sudan. [email protected].

PMID: 28795273 DOI: 10.1007/s11604-017-0671-6

Abstract

Radiotherapy is the ionizing radiation used for treatment of cancer and other diseases. Although radiotherapy is the major treatment for cancer, a lot of patients do not undergo radiation due to associated risks such as radiation pneumonitis, cardiovascular complications, development of secondary tumor, and lymphedema. However, the advantages of nanotechnology provide a unique potential to enhance radiotherapeutic performance, in particular by utilizing gold nanoparticles (Au NPs). In this review, we briefly describe the current direction of research towards the use of Au NPs for radiotherapeutic enhancement, combination, monitoring and in side effect reductions.

Keywords: Cancer radiotherapy; Drug resistance; Gold nanoparticles; Radio-sensitizer

References

  1. Nanoscale. 2012 Aug 21;4(16):4830-8 - PubMed
  2. Liver Transpl. 2004 Feb;10(2 Suppl 1):S115-20 - PubMed
  3. Chem Soc Rev. 2012 Mar 21;41(6):2256-82 - PubMed
  4. FEBS Lett. 1991 Apr 9;281(1-2):9-19 - PubMed
  5. J Control Release. 2013 Dec 28;172(3):1020-34 - PubMed
  6. J Control Release. 2016 Apr 28;228:141-149 - PubMed
  7. Recent Pat Drug Deliv Formul. 2007;1(1):37-51 - PubMed
  8. Science. 2005 Jan 7;307(5706):58-62 - PubMed
  9. Adv Mater. 2010 Jul 6;22(25):2729-42 - PubMed
  10. Nanomedicine (Lond). 2015 Jul;10(14):2199-228 - PubMed
  11. Phys Med Biol. 2004 Sep 21;49(18):N309-15 - PubMed
  12. Nanomedicine (Lond). 2013 Oct;8(10 ):1601-9 - PubMed
  13. Radiat Res. 2008 Jan;169(1):19-27 - PubMed
  14. Biomacromolecules. 2015 Dec 14;16(12):3980-8 - PubMed
  15. Sci Rep. 2015 Mar 02;5:8669 - PubMed
  16. Radiat Res. 1998 Jul;150(1):92-100 - PubMed
  17. Nat Rev Cancer. 2015 Jul;15(7):409-25 - PubMed
  18. Bioconjug Chem. 2006 May-Jun;17(3):766-72 - PubMed
  19. Nat Rev Clin Oncol. 2015 Sep;12(9):527-40 - PubMed
  20. Sci Rep. 2017 Jun 5;7(1):2748 - PubMed
  21. Clin Transl Oncol. 2014 Jun;16(6):511-6 - PubMed
  22. Biochim Biophys Acta. 2013 May;1833(5):1028-40 - PubMed
  23. J Clin Oncol. 2014 Apr 20;32(12):1173-9 - PubMed
  24. Biosens Bioelectron. 2017 May 15;91:616-622 - PubMed
  25. Chem Soc Rev. 2012 Apr 7;41(7):2606-22 - PubMed
  26. Methods Mol Biol. 2010;596:467-88 - PubMed
  27. ACS Nano. 2012 Oct 23;6(10):9182-90 - PubMed
  28. J Control Release. 2012 Apr 10;159(1):14-26 - PubMed
  29. Transl Cancer Res. 2013 Aug 1;2(4):320-329 - PubMed
  30. Cancer Res. 2008 Sep 15;68(18):7570-8 - PubMed
  31. J Thorac Oncol. 2012 Jan;7(1):177-82 - PubMed
  32. J Drug Target. 2004 May;12(4):205-13 - PubMed
  33. Nano Lett. 2009 May;9(5):1909-15 - PubMed
  34. Clin Transl Oncol. 2013 Aug;15(8):593-601 - PubMed
  35. J Gynecol Oncol. 2016 Jan;27(1):e4 - PubMed
  36. Nat Rev Drug Discov. 2011 Jun;10(6):417-27 - PubMed
  37. Semin Oncol Nurs. 2006 Nov;22(4):212-20 - PubMed
  38. Int J Radiat Oncol Biol Phys. 2013 Jul 1;86(3):463-468 - PubMed
  39. Int J Radiat Biol. 2000 Oct;76(10):1357-64 - PubMed
  40. ACS Nano. 2015 Dec 22;9(12 ):11540-50 - PubMed
  41. Adv Drug Deliv Rev. 2003 Feb 24;55(3):329-47 - PubMed
  42. Int J Pharm. 2017 Mar 30;520(1-2):126-138 - PubMed
  43. FASEB J. 2008 Jan;22(1):276-84 - PubMed
  44. Adv Healthc Mater. 2015 Apr 22;4(6):856-63 - PubMed
  45. Nanomedicine. 2011 Oct;7(5):580-7 - PubMed
  46. Biomaterials. 2005 May;26(15):2713-22 - PubMed
  47. Radiology. 1978 Oct;129(1):199-203 - PubMed
  48. Nanomedicine (Lond). 2015;10(16):2513-25 - PubMed
  49. J Am Heart Assoc. 2017 May 21;6(5):null - PubMed
  50. J Control Release. 2012 Jun 10;160(2):117-34 - PubMed
  51. Rep Pract Oncol Radiother. 2010 Oct 08;15(6):176-80 - PubMed
  52. J Clin Oncol. 2005 Mar 20;23(9):1934-40 - PubMed
  53. Adv Funct Mater. 2014 Jul 16;24(27):4206-4220 - PubMed

Substances

MeSH terms

Publication Types